Fig. 7

Trajectories of MKN1 cells treated with trastuzumab or afatinib. MKN1 cells were treated with 5 μg/ml trastuzumab (Tra), 0.5 μM afatinib (Afa), 5 μg/ml trastuzumab + 0.5 μM afatinib (Tra + Afa) or afatinib solvent DMSO (0.05%). Untreated (untr) cells were used as control. Cell movement was tracked for 7 h to assess approximate average speed. The trajectories of one exemplary film for each condition are shown. The trajectories were color-coded for approximate average speed